D&D Updated Icon

How Soon is Now?

AI Ends the Wait for Better Health.


AI Just Broke the Discovery Timeline.

Until now, the path from promising target to lifesaving medicine has taken years. Cost and complexity keep better lives out of reach, while patients ask: how soon?

That timeline is now collapsing. Artificial intelligence, automation and advanced data systems are rewiring the paradigm of the biopharma discovery and development.

Human expertise drives the outcome. AI resets the tempo.

Now you can model and simulate biological systems in silico. Design and screen molecules digitally. Test entire hypotheses before the first experiment reaches the bench. Remove bottlenecks early and simulate and refine in hours what once took months.

AI just broke the discovery timeline.
For patients asking how soon, the answer is now.

D&D US AI Image

Discovery and Development US 2026

This is where the scientific community responds to that shift.  San Diego, CA. 12 - 13 October 2026.

Over 1,000 senior scientists, R&D leaders and technology innovators from pharma, biotech and AI-driven drug discovery platforms, across two co-located programmes and two full days of science, collaboration and possibility.

Drug Discovery US explores how AI, advanced biology and translational science are reshaping the earliest stages of the pipeline, from target identification and computational chemistry to targeted protein degradation, ADC development, lab automation and neuroscience drug development.

Formulation and Delivery US takes the molecule forward, covering drug product design, delivery science, biologics formulation, RNA and oligonucleotide delivery, and the analytical development that gets candidates to clinic. 

Together they cover the full journey. From target to candidate. From candidate to medicine. Now.

Drug Discovery US Square Image-1

Drug Discovery

Pushing traditional boundaries in pharmaceutical science by accelerating the discovery of novel therapeutics

Formulation & Delivery US Square Image-1

Formulation & Delivery

Championing innovation within formulation and delivery by bringing together thought leaders who can advance complex, next generation drug formats to market

Partner Image

Partner

Showcase your offering to leading pharma and biotech decision makers


Key Event Highlights

An unmissable journey awaits you: from a high-energy AI & Digitalisation Zone to celebrated keynote speakers and insightful roundtable discussions. Discover the moments that will transform your Discovery & Development experience.  

The programme is built around the questions the field is actually asking in 2026.

Keynotes from Paul Workman OBE FRS of the Institute of Cancer Research, London, Dave Hallett of Recursion and Ingo Hartung of Merck Healthcare KGaA. Confirmed speakers from AstraZeneca, GSK, Sanofi, Novartis, Roche, Bayer, AbbVie, Novo Nordisk and Boehringer Ingelheim. 

Invite-only closed-door sessions for senior leaders on where smart capital is flowing, the real impact of AI on workflows, and the winning model for brain health innovation. An AI and Digitisation Zone bringing together the platforms reshaping how discovery works.

And 400 pre-arranged one-to-one meetings connecting the people who need to find each other.

Berlin. 15-16 June. The AI era of drug discovery begins here.

DDEU26 Keynote Supporting Image

Discovery & Development Europe 2025 Programme Highlights

Explore dynamic panels, engaging roundtables, and hands-on workshops designed to drive innovation and foster collaboration in Drug Discovery, Formulation and Delivery including: 

Drug Discovery & Automation Programme - Key Themes

Panel Discussion: Technological Advancements For Novel Target Discovery

  • Application of new technologies in identifying therapeutics for novel or currently undruggable targets
  • Utilising AI/ML
  • Challenges & future opportunities

 

Panellists include Giovanni Spagnolli, Chief Technology Officer, Sibylla Biotech, Ian Roberts, Senior Director, Digital Biology, Healx & Zoran Rankovic, Director, Center for Protein Degradation, The Institute of Cancer Research

Panel Discussion: Novel Platforms & Techniques To Improve Hit Identification

 

•    Optimising Hit discovery
•    Minimising false positives
•    Integration of techniques

 

Moderated by Jonathan Hopper, Vice President Platforms & Founder, OMass Therapeutics

Panel Discussion: Fostering Partnerships & Collaboration In 2025 – as part of our newly introduced Early-Stage R&D Innovation Programme

 

  • Emerging technologies & techniques
  • Cross-sector partnership
  • Open innovation

 

Moderated by Alexander Natz, Secretary General, EUCOPE & panellists from Cicio Holdings, BioAge Labs, European Commission, Pfizer & Business Region Gothenburg

Panel Discussion: Breakthrough Biotech: How Research Leaders Fund The Next Big Idea

 

  • How research leaders identify and support fundable biotech innovations
  • Overcoming early-stage funding gaps in biotech startups
  • The role of research partnerships with pharma, VCs, and industry in startup success
  • What startups can learn from research-backed biotech wins

 


Panellists include Christoph Rösli, Director of Research Bern, CSL Behring & Member of the Selection Board, BaseLaunch; David Jenkinson, Head of Childhood Cancer Translational Challenge, LifeArc; David Dexter, Director of Research, Parkinsons UK 

Fireside Chat: Impact of AI & Big Data in Drug Discovery & Development

 

Panel Discussion: Translational Studies to Support Better Drug Design

  • Bridging the gap between pre-clinical & clinical research
  • Biomarkers & AI/ML in translational research

 

Moderated by Philippe Marc, Executive Director, Global Head of Integrated Data Sciences, Novartis

Panel Discussion: Fostering Collaboration To Accelerate Neurodegenerative Disease Research


•    Pharma, biotech & academic partnerships
•    The need for innovation, data & technology in CNS research
•    Challenges to be solved through collaboration 

Moderated by Emma Mead, Chief Scientific Officer, Alzheimer’s Research UK Oxford Drug Discovery Institute, University of Oxford. Panellists include Knut Biber, Research Fellow & Head of Glial Biology Team, AbbVie; Sarah Jolly, Principal Scientist, LifeArc; Michael Johnson, Professor of Neurology & Genomic Medicine, Imperial College London


Day 2 Breakfast Workshop - LifeArc: Biomarkers In Neurodegenerative Diseases: From Detection To Progression - Are Blood -Based Biomarkers Enough?

  • Beyond blood-based biomarkers?
  • Are we any closer to a solution?
  • Application of AI/ML

Moderated by Manuela Cerina, Scientific Director – Neurodegeneration, LifeArc & Giovanna Lalli, Director of Strategy & Operations, LifeArc

Panel Discussion:
Automation & Robotics In Drug Discovery & Development – Where Are We Now? 


•    Impact of automation 
•    AI/ML  
•    Robotics in lab processes

Moderated by Rekha Lakshmanan, Global Head of Data Office, AstraZeneca

Panellists include: James Love, Vice President Cross Modalities Workflows, Novo Nordisk, Sarah Trice, COO & Head of US Operations, XtalPi & Tom Kissling, pRED Lab Automation Partner, Roche

Day 2 Breakfast Workshop: SiLA & AnIML Splash


•    Splash! Is a unique event for every digital lab enthusiast. It combines an educational part with a hands-on session to try out standards in action. Pick up the details on the popular SiLA and AnIML standards, understand how they work and where you can put them to use. Our hands-on session lets you experience the standards in action firsthand. We’re bringing real and cloud-based instruments and lots of example data sets 
•    Feel free to bring an instrument or your own data

Formulation and Delivery Programme - Key Themes

Panel Discussion: Moving Beyond Oral Delivery

 

•    Nanoparticles
•    Inhalation
•    Transdermal
•    Developments with Oral Delivery

Moderated by Sandor Batkai, Life Science Consultant, Former, Head of Medical Research and Intelligence, Cardior Pharmaceuticals

 

Panellists include:
• Moein Moghimi, Professor of Nanomedicine & Pharmaceutics, School of Pharmacy at Newcastle University 
• Kamalinder Singh, Professor of Pharmaceutical, Technology & Drug Delivery
• Karsten Mäder, Professor, Martin Luter University Halle-Wittenberg

Panel Discussion: Developing New Biotherapeutic Modalities While Ensuring Robustness And Quality In Their Formulations

  • Improve the stability profile of biomolecules
  • New excipients
  • Impact on product quality and stability
  • Alternative ways of formulation

 

Moderated by Amardeep Bhalla, Executive Director, Regeneron

 

Panellists Include: 

• Ramesh Kashi, Former Senior Scientific Director, Bristol-Myers Squibb
• Tanvir Tabish, Director, Early Formulation Development, AstraZeneca
• Jack Palmer, Field Application Scientist, Advanced Instruments
• Martinus Capelle, Scientific Director, Head of Process & Delivery, Johnson & Johnson Innovative Medicine

Roundtable: Discovery And Delivery Of Therapeutics Across The Blood Brain Barrier – Where Are We Now?

  • Challenges of drug delivery across the BBB
  • Advances in nucleic acid brain therapies
  • Future technologies and translational strategies

 

Moderated by Shadi Farhangrazi, Chief Executive Officer, S.M. Discovery Group and Moein Moghimi, Professor of Nanomedicine & Pharmaceutics, School of Pharmacy at Newcastle University

Key Event Highlights

An unmissable journey awaits you: from award winning speakers and insightful workshops, to an exclusive gala dinner. Discover the moments that will transform your Discovery & Development experience. 

The Start-up Zone

Are you developing a cutting-edge therapy, platform or technology? Our Start-Up Zone is designed to support emerging companies looking to increase their visibility, find potential partners or early adopters, and meet their investment goals – connecting them with our community of pharma, investors, and mid-to-large size biotechs.

Located in the Exhibition Hall, the Start-Up Zone allows therapeutic pioneers to showcase their approach, conduct invaluable 1:1 meetings and deliver a quick-fire pitch.

There are two options, based on the size of your organisation with prices starting from €1020. 

For further information and to get started submit the application form below.

Criteria:

The Start-Up Zone is designed for therapeutic start-ups, academic spin-outs, and early-stage technology/service providers.

 

To be eligible for inclusion, you must meet the following criteria:

 

•    0 – 5 years operating
•    0 – 30 employees
•    Pre-Series A funding


What you will receive:

  • 1 full conference pass
  • 10-minute pitch on the Start-Up Stage
  • 1x1m space in Start-Up Zone for own partnering meetings; cocktail table provided, start-up to bring 1x pull-up banner
  • Logo featured on website & event platform as a participating start-up
  • Ability to arrange 1:1 meetings via the congress app

 

New Opportunities

Discovery & Development Young Scientist Awards

The Discovery & Development Young Scientist Poster Award recognises exceptional individual achievements in scientific research by PhD students, PostDocs, and early-career scientists.

The top three winners receiving the highest scores will be given a trophy, a £1,000 contribution towards travel costs, access to our LifeScienceXchange Pass, and the opportunity to present on the programme.

Three runner ups will be provided with the opportunity to present their work on the programme as well as access to the LifeScienceXchange Pass.

Included in the LifeScienceXchange Pass – 12 months access to expertly curated content, monthly thought leadership sessions & technology showcases.

NextGen Biomed - New Opportunities YSA

Featured Speakers for Discovery & Development US 2026

,
Abhijat Vatsyayan
Head of Artificial Intelligence & Innovation,
Taiho Oncology
Adam Renslo
Professor of Pharmaceutical Chemistry & Vice Dean for Entrepreneurship and Industry Relations,
University of California San Francisco
Adamo Sulpizi
"New Drug Delivery & Projects" Unit Manager,
Chiesi
Adrian Grzybowski
Chief Scientific Officer & Co-Founder,
Anubio
Alexander Macpherson
Executive Director - Novel Platforms,
Eli Lilly
Alexander Taguchi
Director of Machine Learning,
iBio, Inc.
Anil Gupta
Director,
Calibr-Skaggs Institute for Innovative Medicines
Anindya Bhattacharya, Ph. D
Vice President, Head of Neuroscience,
Switch Therapeutics
Arthur Liberzon
Director, AI Research Lead for Omics, Oncology Data Science,
AstraZeneca
Ashley Buckle
Co-Founder & Chief Technology Officer,
Scudo Biosciences
Craig Behnke
EVP Production,
Lumen Bioscience
Denise Steckel
Industry Clinical Collaborations Lead,
Genentech
Ed Addison
Professor of the Practice,
North Carolina State University
Eddie Ray Watts
Vice President, High Throughput Chemistry,
Insitro
Elisabeth Kersten
Formulation Development Leader,
Vividion
Gian Luca Araldi
Chief Executive Officer,
Avanti Biosciences, Inc.
Hongfeng Deng
Vice President, Chemistry | mRNA Center Of Excellent,
Sanofi
Hyunhong James Min
Senior Scientist,
Pfizer Ltd
Isabelle Naeije
Clinical Operations Learning Manager,
Novartis
Jadwiga Bienkowska
Senior Director, Head of Computational Biology, Oncology Research,
Pfizer Ltd
Jian Zhou
Scientist,
Novo Nordisk
Jian Zuo
Co-Founder & Chief Executive Officer,
Ting Therapeutics
Jitendra Kumar
Lead Scientist ,
Entos Pharmaceuticals
Kanika Sarpal
Senior Scientist,
Sanofi
Lauren Tyra
Chief Executive Officer,
Gregor Diagnostics
Margaret Braunreuther
Senior Scientist I,
AbbVie
Marina Nelen
Vice President, Head of Drug Discovery,
Foghorn Therapeutics
Mark Eccleston
CEO,
Valirx
Matthew Fera
Process Development Engineer,
Neurotech Pharmaceuticals
Muthiah (Mano) Manoharan
Senior Vice President, Innovation Chemistry & Alnylam Distinguished Scientist,
Alnylam Pharmaceuticals
Navpreet Kaur
Principal Scientist,
Sanofi
Pin-Kuang Lai
Assistant Professor,
Stevens Institute of Technology
Ping Wee
Lead,
Entos Pharmaceuticals
Raj Thakur
Professor in Pharmaceutics & Founder and CTO,
Queens Univeristy Belfast & Re-Vana Therapeutics
Ramesh Dasari
Principal Scientist,
Sanofi
Richard Bonneau
VP Machine Learning for Drug Discovery, gRED Computational Sciences,
NYU college
Ryan Kole
CEO & Co-Founder,
BBT
Sam Tetlow
Chief Executive Officer,
Grant Engine
Sandeep Yadav
Vice President, Technical Development,
Sangamo Therapeutics, Inc.
Santosh Kesarpu
Associate Director, Formulation Research & Development,
Granules Pharmaceuticals Inc
Scott Thacher
CEO and founder,
Orphagen Pharmaceuticals
Shital Mehta
Principal Scientist,
Vividion Therapeutics
Shyam Ramachandran
Cluster Head, Neuroscience,
Sanofi
Tao Wang
Senior Manager,
GSK
Trevor Smith
Vice President,
Inovio
Vivek Gupta
Associate Professor and Scientific Founder,
St. John University

Interested in Sponsoring NextGen Omics & Spatial Biology US 2025?

Become a driving force in accelerating the next generation of multi-omics-based treatments. NextGen Omics & Spatial Biology US offers a unique platform to enhance your brand visibility and connect with thousands of pharma, biotech, & academic experts. Our branded event opportunities, immersive experiences, and content services enable you to engage, educate, & collaborate with the community shaping the future of genomic medicine today.

Interested in Sponsoring NextGen Biomed?

Become a driving force in accelerating the next generation of biologics and immunotherapy medicines to patients. NextGen Biomed offers a unique platform to enhance your brand visibility and connect with thousands of pharma, biotech, and R&D experts. Our branded event opportunities, immersive experiences, and content services enable you to engage, educate, and collaborate with the community shaping the future of biomedicine today.

Getting There

Hilton San Diego Bayfront
1 Park Blvd, San Diego, CA 92101, United States

By Air – San Diego International Airport  The Hilton San Diego Bayfront hotel is still about 3 miles away from the San Diego International Airport. A single taxi ride to the hotel will now generally cost around $15–$20 and takes about 15–20 minutes depending on traffic. Rideshare options (Uber/Lyft) are available and vary by demand, often in the $17–$25+ range. There isn’t a hotel-run airport shuttle provided directly by Hilton Bayfront; instead you can use local public transit or arrange private shuttle services if needed.

By Bus – Several bus stops and transit lines serve the area near the Hilton San Diego Bayfront. The nearest frequent bus stops are around Market St & 6th Ave, 10th Ave & Island Ave, and Park Blvd & 10th Ave, all within walking distance of the hotel. These bus lines stopping nearby include 3, 12, 901, 929 (and others depending on direction). The closest major transit hub is the 12th & Imperial Transit Center, about a 9–12 min walk away. Additionally, the San Diego trolley (light rail) lines - such as the BLUE and GREEN lines - service stops within walking distance to the hotel.

By Ferry – The nearest ferry station to the hotel is 5th Ave Pier, which is about a 6–7 minute walk from Hilton San Diego Bayfront. This is convenient for riders using the Coronado Ferry across San Diego Bay.

Parking – The Hilton San Diego Bayfront offers self-parking for our guests at $25 per day and valet parking rates can be found at the hotel reception. Rates are subject to change.

Information regarding accommodation for this event will be added soon

We are closely monitoring the official guidance from health authorities, local governments, and the World Health Organization in order to support the health and well-being of our global community. The health and safety of our staff, customers and clients remains our number one priority.

As we continue to move forward with hosting our events in-person in 2024, we’ve added a series of Health & Safety guidelines and precautions in order to prepare for event safety. We carry out risk assessments for all our events to evaluate fundamental considerations and how to cover multiple risk scenarios.

Oxford Global has learned that third-party companies (recently EHotel Services, Business Travel Management/btravelmanagement and Exhibitors Hotel Reservations Services) are targeting conference attendees with a fraudulent hotel booking scheme.

Please note that none of these third-party companies are associated with Oxford Global in any way, nor have Oxford Global authorised them to use their names or trademarks on information they send out to attendees.

If you are contacted by a third-party company by phone or email using Oxford Global’s name or the name of Discovery & Development US 2026 and offering accommodation services, we urge exhibitors and attendees to proceed with extreme caution before signing anything sent by these companies or entering into any conversation or replying to any emails sent from these third-party companies.

D&D + LSX Combined Logo

Unlock the Latest News and Insights

Sign-up for our regular LifeScienceXchange newsletter to keep up to date with all things Discovery & Development, direct to your inbox.

D&D Newsletter Icon-1

2025 Young Scientist Awards (YSA) for Best Poster Presentation

The NextGen Biomed Young Scientist Awards include the best poster presentation award and are intended to honour an outstanding individual performance for a scientific work by a PhD student, PostDoc or early career scientist.

Please submit your poster presentation by no later than 13th January 2025 in the below category:

  • Protein/Antibody Engineering
  • Bioanalysis & Characterisation
  • Next Generation Biotherapeutics
  • Peptides Chemistry & Therapeutics
  • Oligonucleotides Chemistry & Therapeutics
  • Sustainable Chemistry & Manufacturing
  • Student (PhD), PostDoc or early career scientist under 35 years of age. Proof must be provided via an active student ID card or a copy of status
  • Applicants must be the first AND presenting author of the submitted paper and register for the meeting by 13th January 2025
  • ONLY ONE YSA submission per person will be accepted. If authors submit multiple abstracts for consideration for the YSA, only one abstract will be taken into consideration for the YSA

Applicants must follow the procedure as follows: 

  • Register and submit an abstract by 13th January 2025 using the registration link to the left on this page 
  • Once registered you will be provided with the online abstract submission form 
  • Prepare the poster or platform and present it (The poster presenter should be at the poster during all breaks.) 
  • The 3 winners with the highest scores will be announced at the Networking Drinks on the second day of the event 
  • The winners’ 10-minute oral presentations will take place during the networking drinks on day 2 

The platform or poster presentation will be evaluated by senior scientists (consisting of our speaking and steering group committee for the NextGen Biomed series) on the basis of originality of the approach and quality of the work (e.g. appropriate methodology, interpretation of results, conclusiveness). All participants will receive the scoring and comments after the annual meeting via email.

The 3 winners receiving the highest scores will be announced at the Networking Drinks on the Day 2 and will be given a trophy as well as £1,000 contribution towards travel costs. Oxford Global will also provide winners with PLUS Pass – 12 months access to our content platform providing access to on-demand presentations, exclusive reports and highlights. 

D&D + LSX Combined Logo

Unlock the Latest News and Insights

Sign-up for our regular LifeScienceXchange newsletter to keep up to date with all things Discovery & Development, direct to your inbox.

D&D Newsletter Icon-1

Interested in Discovery & Development US 2026?